MONTEVIDEO, Uruguay & NEW YORK, United States, April 7, 2026
Resolve Therapeutics and the Institut Pasteur de Montevideo announced a strategic research collaboration to identify cell-free RNA (cfRNA) triggers driving autoimmune diseases, aiming to uncover upstream molecular mechanisms responsible for chronic inflammation in conditions such as lupus and Sjögren’s syndrome. The partnership integrates next-generation sequencing technology with clinical development programs, marking a significant advancement in precision medicine and autoimmune disease research.
Innovative Sequencing Technology Unlocks Hidden Disease Drivers
At the core of the collaboration is REJOIN-seq, a novel sequencing platform developed by the Institut Pasteur that enables the restoration and analysis of fragmented and degraded cfRNA molecules, which are typically missed by conventional sequencing methods. This breakthrough technology allows researchers to capture previously undetectable RNA signals, providing a deeper understanding of the molecular triggers initiating autoimmune inflammation.
Cell-free RNA, including damaged self-RNA and endogenous retroviral RNA, plays a critical role in activating self-perpetuating inflammatory cascades. However, due to its fragile nature, traditional sequencing approaches often fail to detect these molecules, limiting insights into disease mechanisms. By leveraging REJOIN-seq, the collaboration aims to generate high-resolution molecular data, enabling the identification of key upstream triggers that drive immune dysregulation.
This approach represents a major step forward in biopharmaceutical research, as it bridges the gap between basic science innovation and clinical application, providing a more comprehensive understanding of autoimmune disease biology.
Advertisement
Advancing Non-Immunosuppressive Therapeutic Strategies
Resolve Therapeutics is focused on developing next-generation, non-immunosuppressive therapies targeting cfRNA and neutrophil extracellular traps (NETs), which are implicated in chronic inflammation and tissue damage. By integrating REJOIN-seq into its clinical programs, the company aims to enhance biomarker discovery, improve patient stratification, and optimize therapeutic development.
The collaboration is expected to accelerate the development of innovative treatment approaches that address the root causes of autoimmune diseases, rather than broadly suppressing the immune system. This is particularly important in conditions like lupus and Sjögren’s syndrome, where current therapies often have limited efficacy and significant side effects.
Resolve’s lead clinical candidate, RSLV-132, has already demonstrated clinical activity in randomized trials, while its next-generation asset RSLV-145 is being developed for acute inflammatory conditions such as ischemic stroke. The integration of advanced sequencing data is expected to further strengthen the company’s drug development pipeline and precision medicine strategy.
Bridging Basic Science and Clinical Innovation
The collaboration highlights the importance of combining cutting-edge academic research with clinical-stage biopharmaceutical development. The Institut Pasteur de Montevideo brings expertise in functional genomics and RNA biology, while Resolve contributes clinical data, therapeutic platforms, and translational research capabilities.
This partnership reflects a growing trend in the industry toward data-driven drug discovery, where advanced technologies such as AI, genomics, and molecular sequencing are used to uncover previously hidden disease mechanisms. By identifying the earliest triggers of inflammation, researchers can develop more targeted and effective therapies, ultimately improving patient outcomes.
The collaboration also reinforces the global nature of modern biomedical research, bringing together international expertise to tackle complex diseases that affect millions of patients worldwide.
The partnership between Resolve Therapeutics and the Institut Pasteur de Montevideo represents a significant advancement in autoimmune disease research, leveraging innovative sequencing technology to uncover critical molecular drivers of inflammation. By focusing on cell-free RNA as a central trigger, the collaboration has the potential to transform the understanding and treatment of autoimmune conditions.
As the field of precision medicine continues to evolve, integrating advanced genomics with clinical development will be essential for delivering next-generation therapies that are more targeted, effective, and safer for patients.
Source: Resolve Therapeutics press release
